These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8470921)

  • 1. [Pharmacokinetics and antitumor activity of MX2, a new morpholino anthracycline in brain tumor intracerebral transplanted in rats].
    Kiya K; Ogasawara H; Fujita H; Sugiyama K; Kurisu K; Kawamoto K; Uozumi T; Shinkai H
    Gan To Kagaku Ryoho; 1993 Apr; 20(5):631-5. PubMed ID: 8470921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of MX2, a new morpholino anthracycline, against experimental brain tumors.
    Izumoto S; Arita N; Hayakawa T; Ohnishi T; Taki T; Yamamoto H; Ushio Y
    Anticancer Res; 1990; 10(3):735-9. PubMed ID: 2369088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.
    Park SJ; Kaye AH; Hill JS
    J Clin Neurosci; 2000 Jan; 7(1):42-7. PubMed ID: 10847650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of MX2, a new morpholino anthracycline, in CSF following intravenous injection].
    Yamamoto H; Arita N; Ohnishi T; Hiraga S; Izumoto S; Taki T; Higuchi M; Hayakawa T; Shinkai H
    Gan To Kagaku Ryoho; 1993 Jul; 20(9):1227-30. PubMed ID: 8333749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumor effect of a new anthracycline derivative, MX2, against human glioma cells].
    Kuratsu J; Mihara Y; Kochi M; Takaki S; Ushio Y
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):399-403. PubMed ID: 2930204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Distribution and acute toxicity of a new morpholinoanthracycline, MX2, in normal rat brain after intra-arterial injection].
    Izumoto S; Arita N; Hayakawa T; Ohnishi T; Hiraga S; Taki T; Yamamoto H
    Gan To Kagaku Ryoho; 1991 Mar; 18(3):371-5. PubMed ID: 2003739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antitumor effect of MX2, a new morpholino anthracycline, against malignant glioma cell lines and its subcellular distribution.
    Kabuto M; Kubota T; Kobayashi H; Nakagawa T; Kitai R
    Neurosurgery; 1995 Sep; 37(3):471-6; discussion 476-7. PubMed ID: 7501112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antitumor effect of MX2, a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro].
    Kabuto M; Kubota T; Kobayashi H; Nakagawa T; Kitai R; Uno H; Kodera T
    No To Shinkei; 1995 Oct; 47(10):969-73. PubMed ID: 7577142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of MX-2, a morpholino anthracycline derivative, against human and rat glioma cells and experimental leptomeningeal tumors in rats].
    Izumoto S; Arita N; Ushio Y; Hayakawa T; Ohnishi T; Taki T; Yamamoto H; Oku Y; Mogami H; Komeshima N
    Gan To Kagaku Ryoho; 1988 May; 15(5):1765-9. PubMed ID: 3369870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
    Watanabe M; Komeshima N; Nakajima S; Tsuruo T
    Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic efficacy of intracarotid infusion of 20% mannitol with ACNU in Fischer rats with intracerebrally implanted 9L gliosarcoma].
    Miyagami M; Tazoe M; Kasahara E; Tsubokawa T
    Gan To Kagaku Ryoho; 1989 May; 16(5):2059-65. PubMed ID: 2499268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [MCNU delivery into malignant brain tumor and normal brain tissue by intravenous or intraarterial infusion].
    Miyagami M; Tazoe M; Tsubokawa T
    Gan To Kagaku Ryoho; 1990 Feb; 17(2):275-80. PubMed ID: 2154161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
    Watanabe M; Komeshima N; Naito M; Isoe T; Otake N; Tsuruo T
    Cancer Res; 1991 Jan; 51(1):157-61. PubMed ID: 1988080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcellular localization and cellular pharmacokinetics of MX2, a new morpholino anthracycline in glioma cells using confocal laser scanning microscopy.
    Kabuto M; Kubota T; Kobayashi H; Nakagawa T; Arai Y; Kitai R
    Neurol Res; 1994 Aug; 16(4):257-64. PubMed ID: 7984256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect and peritumoral brain edema formation in relation to MX2, ACNU, and doxorubicin therapy: a comparative analysis using rodent models of gliomas.
    Mima T; Mostafa MG; Mori K
    Neurol Res; 2000 Dec; 22(8):819-24. PubMed ID: 11149245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of apoptosis in megakaryocytic leukemia cell lines by MX2, a morpholino anthracycline.
    Katsurada T; Adachi M; Kido H; Date M; Kishimoto Y; Yamanaka Y; Kimura T; Fukuhara S
    Exp Hematol; 1997 Sep; 25(10):1077-83. PubMed ID: 9293905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice.
    Shinkai H; Takahashi H; Miyamoto K; Uchida T; Tokiwa T
    Cancer Chemother Pharmacol; 1996; 38(5):417-24. PubMed ID: 8765434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.
    Morgan DJ; Hill JS; Clarke K; Stylli SS; Park SJ; Cebon J; Basser RL; Kaye AH; Geldard H; Maher DW; Green MD
    Cancer Chemother Pharmacol; 1997; 40(3):202-8. PubMed ID: 9219502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model.
    Kaiser MG; Parsa AT; Fine RL; Hall JS; Chakrabarti I; Bruce JN
    Neurosurgery; 2000 Dec; 47(6):1391-8; discussion 1398-9. PubMed ID: 11126910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma.
    Kuratsu J; Arita N; Kurisu K; Uozumi T; Hayakawa T; Ushio Y
    J Neurooncol; 1999 Apr; 42(2):177-81. PubMed ID: 10421076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.